Analyst Price Targets — AZN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 10, 2025 11:14 am | — | HSBC | $108.00 | $89.82 | TheFly | AstraZeneca price target raised to $108 from $95 at HSBC |
| December 3, 2025 11:30 am | — | Morgan Stanley | $103.00 | $90.17 | TheFly | AstraZeneca price target raised to $103 from $93 at Morgan Stanley |
| July 9, 2025 7:38 pm | Luisa Hector | Berenberg Bank | $97.00 | $70.82 | TheFly | AstraZeneca price target raised to $97 from $93 at Berenberg |
| November 13, 2024 1:13 pm | Etzer Darout | BMO Capital | $88.00 | $81.19 | StreetInsider | AstraZeneca (AZN) PT Lowered to $88 at BMO Capital |
| September 11, 2024 8:18 am | Etzer Darout | BMO Capital | $89.00 | $79.94 | StreetInsider | BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN) |
| May 30, 2024 7:07 am | John Eade | Argus Research | $85.00 | $76.84 | StreetInsider | AstraZeneca (AZN) PT Raised to $85 at Argus |
| May 28, 2024 9:20 am | Etzer Darout | BMO Capital | $82.00 | $76.74 | StreetInsider | BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN) |
| July 12, 2023 8:44 am | Andrew Berens | Leerink Partners | $79.00 | $64.86 | Benzinga | These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts |
| January 5, 2023 7:01 am | — | BMO Capital | $82.00 | $69.50 | Benzinga | BMO Capital Initiates Coverage On AstraZeneca with Outperform Rating, Announces Price Target of $82 |
| November 11, 2022 3:58 am | — | Leerink Partners | $78.00 | $65.09 | Benzinga | SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $78 |
Latest News for AZN
American Century Companies Inc. raised its stake in AstraZeneca PLC (NASDAQ: AZN) by 40.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,187,050 shares of the company's stock after purchasing an additional 626,724 shares during the quarter. American
Shares of AstraZeneca PLC (NASDAQ: AZN - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 1-year target price
For 2025, we underperformed the Benchmark, while to a lesser extent also trailing our all-cap international growth Proxy Benchmark. The underperformance was in our view attributable to an abrupt but material correction in several holdings over the potential exposure of quality growth franchises to AI disruption. Lundin Mining Corporation shares rose meaningfully during the fourth quarter after the company raised its…
Mustang Bio (NASDAQ: MBIO - Get Free Report) and AstraZeneca (NASDAQ: AZN - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of current recommendations
The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS, driving an increase to its price target and reiterated 'buy' rating. Analyst Matthew Weston said the company and the wider sector face a "significant patent cliff" around 2030-and-beyond but argues the FTSE 100 drugmaker is well positioned to manage this with…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for AZN.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.